TimesSquare Capital Management’s Puma Biotechnology PBYI Stock Holding History

TimesSquare Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-72,500	Closed	-$17.1M	–	260
2015 Q1	$17.1M	Sell	72,500 -9,700	-12%	-$2.07M	0.09%	219
2014 Q4	$15.6M	Sell	82,200 -4,050	-5%	-$899K	0.09%	214
2014 Q3	$20.6M	Buy	86,250 +85,850	+21,463%	+$17.6M	0.12%	213
2014 Q2	$26K	Buy	+400	New	+$28.4K	﹤0.01%	240

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TimesSquare Capital Management's PBYI Position: Q2 2015 in Review

TimesSquare Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2015, closing a stake of 72,500 shares — an estimated $17.1M sold.

TimesSquare Capital Management first reported a position in PBYI in Q2 2014 and held it in 4 quarters. The position peaked at $20.6M in Q3 2014. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

TimesSquare Capital Management reported no remaining Puma Biotechnology position as of Q2 2015 after selling out during the quarter.
TimesSquare Capital Management sold 72,500 Puma Biotechnology shares in Q2 2015, an estimated $17.1M.
TimesSquare Capital Management first reported a position in Puma Biotechnology in Q2 2014 and held it in 4 quarters.
TimesSquare Capital Management's Puma Biotechnology position peaked at $20.6M in Q3 2014.
198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on TimesSquare Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.